Merck - Factbites

Merck - Factbites
Where results make sense
About us | Why use us? | Reviews | PR | Contact us

Topic: Merck

Note: these results are not from the primary (high quality) database.

In the News (Mon 21 Dec 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

	Merck & Co. - Wikipedia, the free encyclopedia
		Merck and Co. traces its origins to Friedrich Jacob Merck (1668) and Emanuel Merck (1816) of Darmstadt, Hesse.
		The position of Merck at the time was that there was no indication of this risk in the original placebo-controlled safety trials, and that it was possible that the effect was more related to Naproxen decreasing the risk of heart attacks than one of Vioxx increasing the risk.
		Merck and Co., Inc. NYSE: MRK or Merck Sharp and Dohme (as it is known outside the USA and Canada) is a US pharmaceutical company.
	en.wikipedia.org /wiki/Merck_&_Co. (837 words)

	The Motley Fool: Dueling Fools, Merck Bear's Den
		Merck is counting on Vioxx to replace much of the revenue it will lose from patent expirations, and it apparently is a significant advance in its field, but given the competition, it's no Viagra.
		Merck's other major products aren't losing their patents, but its is losing market share as their rivals develop competing, and in some cases better, drugs.
		Merck's newest drugs will not be able to fully replace the revenue: Propecia, for hair-loss replacement; Maxalt, for migraines; Singulair, an asthma drug; Aggrastat, an anti-coagulant; Vioxx, an anti-arthritic pain reliever, and Cosopt, for treatment of glaucoma, will be lucky to generate $3.5 billion in sales by 2001.
	www.fool.com /DuelingFools/1998/DuelingFools981111mrk002.htm (942 words)

	Merck Wien GmbH - Forschung - Innovation
		Merck setzt bei der Krebsforschung auf vier Technologieplattformen (Monoklonale Antikörper, Krebsimpfstoffe, Immunozytokine und Angiogenese-Inhibitoren).
		Merck ist eines der ältesten forschenden Unternehmen der Welt.
		Lesen Sie mehr zum Thema Innovation auf der Homepage der Merck KGaA Darmstadt.
	www.merck.at /forschung/forschung.htm (280 words)

	Merck
		Merck and Co. has been cited by federal regulators for numerous quality-control problems at a manufacturing plant where several important vaccines are made.
		For their part, Merck and other vaccine makers, along with many government health officials and scientists, say there is no credible evidence of harm from the amounts of mercury once widely present in kids' shots.
		A memo from Merck and Co. shows that, nearly a decade before the first public disclosure, senior executives were concerned that infants were getting an elevated dose of mercury in vaccinations containing a widely used sterilizing agent.
	www.vaccinetruth.org /merck.htm (2051 words)

	The Murky History of Merck's Vioxx
		Merck later speculates that the difference is caused by the heart-protective effect of naproxen rather than the heart-risk effect of Vioxx.
		Merck's (MRK :NYSE - commentary - research) decision to withdraw its popular arthritis drug Vioxx from the market in late September has raised questions about the process leading up to its regulatory approval in 1999 as well as the importance of subsequent medical studies.
		Merck says rates of cardiovascular risk were "similar" among patients taking Vioxx, placebo or other pain relievers.
	www.thestreet.com /_googlen/stocks/biotech/10195104.html?cm_ven=GOOGLEN&cm_cat=FREE&cm_ite=NA (602 words)

	Merck
		Merck manufacturing managers recognized that the lack of efficiency in the CNC programming process was becoming a major problem.
		In many countries Merck is one of the major suppliers in the generic drug industry thanks to its ability to bring these drugs to market quickly.
		Merck has 192 operating companies in 55 countries and production facilities in 60 locations in 27 countries.
	www.dptechnology.com /Success_Stories/Merck/Merck.htm (1525 words)

	The Trentonian - News - 11/07/2004 - Vioxx shockwaves rock Merck
		A Merck employee for more than three years, Zeph Ugwuneri is serving as the lead plaintiff for a class- action lawsuit filed by Scott & Scott LLC and Cohn Lifland Pearlman Herrman & Knopf LLP, on behalf of all of Merck’s employees and its retirees participating in the Employee Savings and Security Plan.
		When Merck removed Vioxx, a rofecoxib, part of the Cox-2 inhibitor class of drugs, it was based upon a new, three-year APPROVe (Adenomatous Polyp Prevention) study that revealed patients taking Vioxx more than 18 months increased their risk for heart attacks and strokes.
		Merck removed Vioxx after a three-year study revealed patients taking Vioxx more than 18 months increased their risk for heart attacks and strokes.
	www.zwire.com /site/news.cfm?newsid=13312847&BRD=1697&PAG=461&dept_id=44551&rfi=6 (1144 words)

	Merck Institute for Science Education
		The Merck Institute for Science Education was created in 1992 to coordinate and focus the science education reform efforts of Merck and Co., Inc. Its mission is to improve the quality of science education during the formative years of kindergarten through eight grade.
		Merck Institute leadership is promoting the dissemination of its model programs through distribution of comprehensive yearly reports, prepared by the Consortium for Policy Research in Education (CPRE) at the University of Pennsylvania, as part of CPRE's long-term evaluation of Institute programs.
		The primary goal of the Merck Institute for Science Education is to provide all children with strong, inquiry-centered instruction that meets the emerging national standards in science, thereby raising levels of student performance.
	www.nas.edu /rise/examp67.htm (1097 words)

	Merck & Co., Inc., - Investment Prospectus
		Merck reserves the right to deny, modify, suspend or terminate participation in the Plan by otherwise eligible persons to the extent Merck deems it advisable or necessary in its discretion to comply with applicable laws or to eliminate practices that are not consistent with the purposes of the Plan.
		Merck provides a more detailed description of its current business and industry segments, including an overview of the regulatory environment within which it and its subsidiaries operate, in its annual report on Form 10 K filed with the Commission and incorporated by reference herein.
		Also, all documents filed by Merck with the Commission pursuant to Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act after the date of this Prospectus and prior to termination of this offering shall be deemed to be incorporated by reference herein and to be a part hereof from the date of such filing.
	www.wellsfargo.com /com/shareowner_services/services_for_shareholders/investment_plan/merck.jhtml?rld (6609 words)

	Merck - Wikipedia, the free encyclopedia
		Merck Records, an IDM record label based in Miami, Florida.
		Merck and Co., Inc. (aka Merck Sharp and Dohme), the U.S. pharmaceutical company spun off from the german Merck KGaA
		the Merck Index, an encyclopedia of Chemistry, published by Merck and Co.
	en.wikipedia.org /wiki/Merck (117 words)

	How murky is Merck outlook? - Dec. 6, 2004
		Merck is the cheapest big pharma stock and has the highest yield...but rivals have better growth prospects and their dividends aren't shabby either.
		There were some rumblings last week about Merck being a target since the company disclosed in a filing with the Securities and Exchange Commission that it had adopted lucrative severance plans for top executives in the event of a change in control at the company.
		He said Merck's most promising one is Muraglitazar, a drug it is co-developing with Brystol-Myers Squibb to lower blood sugar and cholesterol in diabetes patients.
	money.cnn.com /2004/12/06/news/fortune500/merck (880 words)

	USATODAY.com - Lawyer: Merck more about profits than healing
		Merck knowingly put patients at risk by relying on limited animal studies to say its arthritis drug Vioxx would not harm the heart and ignoring human data that suggested otherwise, an advocacy group said Thursday.
		Merck says the company responsibly researched Vioxx's safety in numerous clinical trials before the U.S. Food and Drug Administration approved it and monitored the drug after it went on the market in 1999.
		Vioxx was critical to Merck, Lanier said, because patents on other lucrative drugs ran out in 2000 and 2001 and "if Vioxx doesn't fill up the ATM machine for us, we're running dry.
	www.usatoday.com /money/industries/health/drugs/2005-07-14-vioxx-trial_x.htm (753 words)

	Vioxx news slams Merck stock - Friday, 10/01/04
		Merck and Co.'s shares plunged yesterday on news that the pharmaceutical company was withdrawing Vioxx, the world's second-best-selling painkiller, because of a potential link to heart attacks and strokes.
		Merck is threatened with the loss of U.S. exclusivity in 2006 for the cholesterol treatment Zocor.
		Merck, along with Pfizer and Johnson and Johnson, are among the seven U.S. industrial companies with perfect credit ratings from Moody's Investors Service and SandP.
	www.tennessean.com /business/archives/04/09/58779741.shtml?Element_ID=58779741 (874 words)

	Report: Merck Played Down Vioxx Risks
		Merck withdrew Vioxx from the market on Sept. 30, saying that a company-sponsored study had shown that long-term use of the drug -- longer than 18 months -- raised the risk of cardiovascular problems when test results of Vioxx users were compared with people taking placebo.
		Merck didn't identify the documents or the court.
		For several years before and after Vioxx was approved for commercial use, executives of Merck (MRK:NYSE - commentary - research) were reportedly aware of -- and tried to play down -- the drug's potential risk for causing cardiovascular problems such as heart attack and stroke.
	thestreet.com /_yahoo/stocks/biotech/10191714.html?cm_ven=YAHOO&... (481 words)

	Merck & Co.
		Although Merck has some promising products in the pipeline, such as Zetia for cholesterol reduction, it is suffering from the expiration of some of its patents; patents for Vasotec and Pepcid expired in 2000 and those for Prinivil and Prilosec expired in 2002.
		One of Merck’s more dramatic successes is HIV drug Crixivan, which reduced AIDS-related deaths by 60 percent after just 18 months on the market.
		Merck also produces arthritis treatment Vioxx and cholesterol treatment Zocor, its biggest seller.
	www.wetfeet.com /asp/companyprofiles.asp?companypk=142 (228 words)

	Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first.
		Merck and Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first.
		Agensys and Merck Announce Agreement to Co-Develop and Commercialize a Novel Antibody for Cancer Therapy
		Merck's position on clinical trials registries and results
	www.merck.com (100 words)

	Human Life International - Merck Boycott - Merck Meeting 2004
		As stockholders in Merck we are particularly distressed at the violation of human rights that occurred in the early 1960s in the development of two cell lines, the RA 27/3 and the WI-38, which were used to create the MMR vaccine.
		After the extraction of the tissues and cultivation of the cell lines Merck became the only licensed manufacturer of the Rubella vaccine in the United States, and to this day continues to profit from the use of aborted babies in your MMR vaccine.
		We are even more distressed that this same pattern of human rights violations continues to take place with the PER-C6 cell line that Merck has taken license for in developing a new AIDS vaccine.
	www.hli.org /merck_merck_meeting2004.html (542 words)

	Merck pulls Vioxx across the globe - Stocks & Economy - MSNBC.com
		Merck said the heart attacks and strokes were not spotted during the first 18 months of the trial but became apparent later.
		30: Merck and Co. Chairman and CEO Raymond Gilmartiin details the pharmaceutical giant's decision to voluntarily recall its blockbuster arthritis drug Vioxx across the globe due to new data suggesting an increased risk of heart attack and stroke.
		Merck said it would continue to market Arcoxia, its newer Cox-2 treatment that is sold in 47 countries.
	www.msnbc.msn.com /id/6139592 (880 words)

	Forbes.com: Street Fight: Merck
		Merck is playing a volume game with their existing products through their distribution channels, and the growth of Medco this year may surprise investors on the upside.
		Merck's standalone P/E is low, but it is not a takeover candidate, so it is unlikely to get a premium valuation.
		Butler: Merck is trading roughly in line with the SandP 500, and the industry has historically traded at a 30% premium to the SandP 500.
	www.forbes.com /2001/06/25/0625streetfight.html (841 words)

	Merck Faces U.S. Investigation Regarding Its Painkiller Vioxx
		Merck, which disclosed the investigations in its quarterly filing with securities regulators, said that the staff of the SEC had told the company that it had begun an informal inquiry.
		Merck did not say what the investigations were about and federal agencies do not as a rule comment on such investigations.
		Merck said on Monday that it had received a subpoena from the Justice Department “requesting information related to the company’s research, marketing and selling activities with respect to Vioxx.” It said the request related to a “federal health care investigation under criminal statutes.”
	www-tech.mit.edu /V124/N52/52_long3.52w.html (311 words)

	merck_coverups.htm
		It was not until September 2004 that Merck put a stop to a separate study when patients in that trial experienced heart attacks and strokes at twice the rate of those receiving a placebo.
		A memo from Merck and Co. showed that, nearly a decade before the first public disclosure, senior executives were concerned that infants were getting an elevated dose of mercury in vaccinations containing a widely used sterilizing agent.
		Now a Merck memo written in 1991 surfaces in which senior executives expressed concerns babies were receiving elevated amounts of mercury from vaccines.
	www.mercola.com /2005/feb/23/merck_coverups.htm (1122 words)

	Kevin, M.D. - Medical Weblog: Vioxx and Merck: Saturday update
		Merck said it was 'disappointed' with the verdict, claiming 'the plaintiff did not meet the standard set by Texas law to prove Vioxx caused Mr Ernst’s death.' There is no reliable scientific evidence that shows Vioxx causes cardiac arrhythmias.
		Merck's defense in the lawsuit seemed to be reasonably strong -- that is, Mr.
		Merck has another cox-2 drug, Arcoxia, that is already approved in 54 other countries and generated worldwide sales of $100 million in the first half of this year."
	www.kevinmd.com /blog/2005/08/vioxx-and-merck-saturday-update.html (1413 words)

	Merck & Co. - Wikipedia, the free encyclopedia
		We don't have an article called "Merck and Co."
		Wait a few minutes, or check the deletion log.
	en.wikipedia.org /wiki/Merck_&_Co. (37 words)

	Bloomberg.com: U.S.
		Merck's liabilities from Vioxx, which was pulled after a study linked it to heart attacks and strokes, may range from $4 billion to $18 billion, Merrill Lynch has estimated.
		Merck's corporate credit and senior unsecured debt ratings were cut three levels to AA-, SandP said in a statement.
		Merck Chief Executive Officer Raymond Gilmartin will be appearing at a Senate hearing Thursday in which lawmakers will examine whether Merck acted fast enough in pulling Vioxx.
	www.bloomberg.com /apps/news?pid=10000103&sid=aepGEeSrdUdk&refer=us (856 words)

	Merck Online Thailand
		Merck Ltd's Chemicals Distribution Center is one of the safest and most modern in Thailand.
		In 1995, Merck Ltd. constructed a Chemicals Distribution Center on a 4,800 sqm plot of land at Bangpoo Industrial Estate (38 km from Bangkok).
		It is driven by close attention to international standards, and to the Merck SHE-policy in particular.
	www.merck.co.th /en/about/social_make_tour.asp (382 words)

	USATODAY.com - Merck halts Vioxx sales
		Merck says the new data — from a three-year study comparing Vioxx with a placebo in 2,600 patients with colon polyps — showed a higher risk of heart attacks and stroke only after 18 months of use.
		In November 2000, Merck published a study in The New England Journal of Medicine that found a higher rate of heart attacks in patients assigned to Vioxx than those assigned to naproxen (an NSAID sold as Aleve).
		Drugmaker Merck (MRK) says 84 million people worldwide have taken the heavily promoted drug, available in the USA since May 1999.
	www.usatoday.com /money/industries/health/drugs/2004-09-30-vioxx-withdrawn_x.htm (551 words)

	CBC News: Merck knew of Vioxx health risks: report
		Merck withdrew it after new data from a clinical trial found an increased risk of heart attack and stroke after 18 months of use.
		After the drug was recalled, Merck reported a 29 per cent drop in its third-quarter profit and cut its year-end earnings guidance.
		Shares of Merck were off $3.03 US to close at $28.28 US following the report in the Wall Street Journal.
	www.cbc.ca /story/business/national/2004/11/01/merck_041101.html (255 words)

	Merck's Missing Vioxx Study - Forbes.com
		Merck spokesman Tony Plohoros says that Merck's statement at the analyst meeting referred to its plan to gather and combine heart-safety data from three other studies, whose primary aim was to show Vioxx could prevent or treat cancer.
		Merck (nyse: MRK - news - people) pulled Vioxx from the market two weeks ago, but questions about the heart safety of the drug date back years, to an August 2001 paper in The Journal of the American Medical Association.
		In December of 2001, Merck seemed to indicate it would mount such a study--but the clinical trial never seems to have materialized, even though the firm started a similar trial for Arcoxia, a successor drug to Vioxx.
	www.forbes.com /sciencesandmedicine/2004/10/14/cx_mh_1014vioxx.html (889 words)

	BW Online March 26, 2004 Turning Merck Around -- Again
		To be fair, Merck has other products in last-stage testing, including a vaccine for human papillomavirus, which causes cervical cancer, and a drug to treat Type II diabetes.
		Merck has only two prescription compounds under final review by the Food and Drug Administration, and neither is fresh.
		Merck's profits have sunk for two years in a row, dragging its share price down to 1998 levels.
	www.businessweek.com /technology/content/mar2004/tc20040326_7650_tc057.htm (1534 words)

	IFPMA Health Initiatives: River Blindness (Onchocerciasis)
		The Merck MECTIZAN® Donation Program (MDP), was launched in 1987, when Merck and Co., Inc. announced that it would donate MECTIZAN® (ivermectin), its breakthrough medicine for the treatment of onchocerciasis (commonly known as “river blindness”) to all who needed it for as long as necessary.
		To date, Merck has donated over one billion Mectizan® tablets worldwide, reaching more than 40 million people a year in 34 countries in Africa, Latin America and Yemen, with more than 300 million cumulative treatments administered since 1987.
		A unique, multisectoral partnership was established with the agreement and cooperation of governments in countries where onchocerciasis is endemic, their ministries of health and other national and international stakeholders to ensure appropriate infrastructure, distribution and support.
	www.ifpma.org /Health/other_infect/health_river.aspx (227 words)

Try your search on: Qwika (all wikis)

Topic: Merck

Ads by Google

Related Topics

In the News (Mon 21 Dec 09)